Healthy Live Blog

In June (2002), the New England Journal of Medicine, digit of the most reputable scrutiny journals, prefabricated a startling announcement. The editors proclaimed that they were descending their contract stipulating that authors of analyse articles of scrutiny studies could not hit playing ties to take companies whose medicines were existence analyzed.

The reason? The aggregation could no individual encounter sufficiency autarkical experts.

Drug consort gifts and “consulting fees” are so general that in whatever presented field, you cannot encounter an proficient who has not been paying soured in whatever artefact by the industry. So the aggregation effected for a newborn standard: Their reviewers crapper hit conventional no more than $10,000 (per year) from “companies whose impact they judge.”

Isn’t that comforting?

This declaration by the New England Journal of Medicine is meet the counsel of the berg of a technological organisation that has been pervasively corrupt by conflicts of welfare and bias, throwing uncertainty on nearly every technological claims prefabricated in the biomedical field.

The accepted declared in June was exclusive for the reviewers. The actualised authors of technological studies in scrutiny journals are ofttimes bought and paying for by clannish take companies, with a wager in the technological results.

While the NEJM and whatever another journals divulge these conflicts, others do not. Unknown to whatever readers is the fact that the accumulation existence discussed was ofttimes composed and analyzed by the concern of the take participating in the test.

In another words, there are whatever deciding treatments for cancer that module not wage Big Pharma a azygos centime of revenue, much inferior profits. This effectuation these aforementioned treatments module not wage the media with a azygos centime of income either.

Guess which treatments the media pushes? In fact, the agent Trade Commission won’t earmark deciding cancer treatments to be advertised, because every of them are “unproven” (translation: not juicy to Big Pharma). There are structure to intend around this FTC rule, much as a aggregation communicator creating an commercial promoting his book.

There is a struggle feat on in penalization today; a struggle between sanctioned (allopathic) penalization and deciding (natural) medicine. The struggle is existence fought with money and information. The struggle is to curb what you know, and don’t know, most cancer treatments.

The struggle is to curb whether you undergo the actuality most every of your cancer communication options.

When a newborn brainstorm is made, the exclusive discourse that is asked is this: “Is it juicy enough?” If the respond is ‘no’ the communication is buried.

Now, perhaps you undergo ground scrutiny costs move to pyrotechnic finished the roof. When a newborn uncolored matter is institute that is proven to blackball cancer cells or kibosh the distribute of cancer, do they communicate whether this matter crapper be utilised in a uncolored communication for cancer? Of instruction not!

The prototypal discourse that is asked is this:

“How crapper we mutate and combine this nutrient, papers it, and attain it into a juicy drug?” And with the media we crapper inhume the uncolored alternative.

Ponder that terminal paragraph carefully, because it is the hunch and feeling of recent medicine. Find a uncolored center that cures something, inhume this fact, then fabricate, synthesize, and mutate the key uncolored substance, then papers the mutation, and attain Brobdingnagian profits.

That is ground there is “no technological evidence” for deciding treatments; no digit is looking, because they cannot be patented and thusly are not juicy enough.

Do you poverty to undergo the mark-up of whatever ordinary drugs?

The U.S. Commerce Department did, and came up with

some engrossing numbers…

Product Name - journalism filler - abstraction - $ retail - $ Mfg Cost - Profit %

Celebrex 100 mg - (100 tablets): $130.27 - $0.60 - 21,712%

Claritin 10 mg - (100 tablets): $215.17 - $0.71 - 30,306%

Norvasc 10 mg - (100 tablets): $188.29 - $0.14 - 134,493%

Prevacid 30 mg - (100 tablets): $44.77 - $1.01 - 34,136%

Prilosec 20 mg - (100 tablets): $360.97 - $0.52 - 69,417%

Prozac 20 mg - (100 tablets) : $247.47 - $0.11 - 224,973%

Tenormin 50 mg - (100 tablets): $104.47 - $0.13 - 80,362%

Vasotec 10 mg - (100 tablets): $102.37 - $0.20 - 51,185%

Xanax 1 mg - (100 tablets) : $136.79 - $0.024 - 569,958%

Big Pharma claims that these prices are needed for them to move with their comprehensive and pricey research, nonnegative the tap efforts to intend a fast approval.

Can you conceive the insolence and boldness of the Big Pharma companies! Most of their mark-up is fashioned to counterbalance another costs, much as lobbyists and advertising. Do you wager what is feat on here? The think there is no authorised “scientific evidence” for deciding cancer treatments and cancer hindrance treatments is that they are not highly juicy when compared to Big Pharma. It is impossible, by law, for a center to be thoughtful to hit “scientific evidence” unless Big Pharma submits it to the bureau (and they afterward okay it), and they module exclusive accede things that are very, rattling juicy to them. That’s meet how playing operates, consumers are not thoughtful important.

It is the Big Plan of Big Pharma to defeat deciding medicine, especially as it relates to their most juicy products, much as cancer drugs, hunch drugs, allergy drugs, etc.

Joni discoverer has whatever eld of comprehensive think in the Atlantic of uncolored cancer hindrance and treatment. He has numerous success stories of grouping existence diagnosed experience cancer liberated with ingest of deciding methods. Ask Joni Bell